AR038985A1 - Parecoxib sodico cristalino - Google Patents

Parecoxib sodico cristalino

Info

Publication number
AR038985A1
AR038985A1 ARP030100915A ARP030100915A AR038985A1 AR 038985 A1 AR038985 A1 AR 038985A1 AR P030100915 A ARP030100915 A AR P030100915A AR P030100915 A ARP030100915 A AR P030100915A AR 038985 A1 AR038985 A1 AR 038985A1
Authority
AR
Argentina
Prior art keywords
solvated
parecoxib
parecoxib sodium
drug substance
sodico
Prior art date
Application number
ARP030100915A
Other languages
English (en)
Spanish (es)
Inventor
Thomas B Borchardt
Leonard J Ferro
Gerald D Danzer
Ahmad Y Sheikh
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR038985A1 publication Critical patent/AR038985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
ARP030100915A 2002-03-15 2003-03-14 Parecoxib sodico cristalino AR038985A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11

Publications (1)

Publication Number Publication Date
AR038985A1 true AR038985A1 (es) 2005-02-02

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100915A AR038985A1 (es) 2002-03-15 2003-03-14 Parecoxib sodico cristalino

Country Status (18)

Country Link
US (1) US20030232871A1 (enExample)
EP (1) EP1485362A1 (enExample)
JP (1) JP2005529084A (enExample)
KR (1) KR100763045B1 (enExample)
CN (1) CN1642926A (enExample)
AR (1) AR038985A1 (enExample)
AU (1) AU2003220180A1 (enExample)
BR (1) BR0308431A (enExample)
CA (1) CA2478500A1 (enExample)
CO (1) CO5631437A2 (enExample)
IL (1) IL163780A0 (enExample)
MX (1) MXPA04008932A (enExample)
MY (1) MY148518A (enExample)
NZ (1) NZ535951A (enExample)
PL (1) PL372880A1 (enExample)
RU (1) RU2300529C2 (enExample)
TW (1) TW200400949A (enExample)
WO (1) WO2003078408A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087682A1 (en) * 2003-04-04 2004-10-14 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
CA2551523A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) * 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英(江苏)药业有限公司 一种帕瑞昔布钠冻干粉针制剂
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英(江苏)药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN117003769B (zh) * 2023-07-11 2024-11-22 中国科学院宁波材料技术与工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
ATE271385T1 (de) * 1996-10-15 2004-08-15 Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
US20030105334A1 (en) * 2001-10-02 2003-06-05 Letendre Leo J. Method for preparing benzenesulfonyl compounds

Also Published As

Publication number Publication date
IL163780A0 (en) 2005-12-18
TW200400949A (en) 2004-01-16
MY148518A (en) 2013-04-30
KR20040095288A (ko) 2004-11-12
KR100763045B1 (ko) 2007-10-04
MXPA04008932A (es) 2004-11-26
JP2005529084A (ja) 2005-09-29
CA2478500A1 (en) 2003-09-25
NZ535951A (en) 2006-02-24
CN1642926A (zh) 2005-07-20
RU2300529C2 (ru) 2007-06-10
RU2004127585A (ru) 2005-04-10
PL372880A1 (en) 2005-08-08
US20030232871A1 (en) 2003-12-18
EP1485362A1 (en) 2004-12-15
AU2003220180A1 (en) 2003-09-29
CO5631437A2 (es) 2006-04-28
BR0308431A (pt) 2005-01-18
WO2003078408A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
BR0014869A (pt) Composição e método para estabilização da mesma
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
LU93066I2 (fr) Combinaison de a) olodatérol, isomèrers optiques individuels de celui-ci, melanges d'énantionmères indiviou de recémates, leurs sels d'addition d'acide avec des acides pharmaceutiquement acceptables, éventuellement sous forme de solvates et/ou hycrates, et b.) un sel de tiotropium ; en particulier une combinaison de a) olodatérol et sis sels d'addition d'acide avec des acides pharmaceutiquement acceptables et b.) du bromure de tiotropium, éventuellement sous forme de solvate et/ou hydrate , plus particulièrement une combinaison de a) hadrochlorure d'olodatérol et b.) de bromure de tiotropium, éventuellement sous forme de monohydrate
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
UY28132A1 (es) Derivados de pirrolopirimidina
UY27446A1 (es) Nuevos compuestos
AR049590A1 (es) Composiciones de limpieza humectantes suaves
ES2185606T3 (es) Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
ES2123721T3 (es) Formulaciones de rapamicina para inyecciones por via intravenosa.
AR033325A1 (es) Composicion que comprende una carnitina y glutationa , util para incrementar la absorcion de la glutationa y sinergizar sus efectos, un complemento dietario, medicamento, la utilizacion de una composicion de combinacion para preparar un complemento dietario o un medicamento
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
AR040036A1 (es) Tratamiento de la mucositis
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
BR0308431A (pt) Parecoxib sódico cristalino
AR018706A1 (es) Uso de una composicion farmaceutica para tratamiento de infecciones virales
MX9300399A (es) Derivados heterotriciclicos.
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure